| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/04/2012 | CN101385696B Sodium alginate microspheres blood vessel suppository containing etoposide and preparation method and uses thereof |
| 01/04/2012 | CN101317821B Ultra-fine dry powder particle suitable for drug administration for lung, and preparation method thereof |
| 01/04/2012 | CN101273134B Glp/1/exendin 4 igg fc fusion constructs for treatment of diabetes and method |
| 01/04/2012 | CN101199590B Lamiophlomis soft capsule containing micropowder silicagel and preparing method thereof |
| 01/04/2012 | CN101180035B Composition for treatment of a detached retina and method of production thereof |
| 01/04/2012 | CN101138543B Centella asiatica partial film forming gel composition and uses thereof |
| 01/04/2012 | CN101094657B Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof |
| 01/04/2012 | CN101022833B Use of glycerol dipalmitostearate for improving the bioavailability of protein active ingredients in subcutaneous or intramuscular injectable formulations |
| 01/03/2012 | US8088934 Composition and method for stabilizing the same |
| 01/03/2012 | US8088916 Hyaluronic acid-methotrexate conjugate |
| 01/03/2012 | US8088734 Bioavailability; amidated in situ; adjustment of pH; protective barrier for stomach |
| 01/03/2012 | US8088605 Exopolysaccharides delivery system for active molecules |
| 01/03/2012 | US8088415 Core-and-shell dosage form or unit in which the core contains API and in which the shell substantially governs the release such as by controlling diffusion of API through the shell. The shell may comprise a release-blocking polymer, and particles |
| 01/03/2012 | US8088411 Crystalline or semi-crystalline trehalose solids having a surface area > 0.25-0.40 m2/g; crystals of trehalose dihydrate and mixtures with anhydrous trehalose; hydrophobic; storage stabiity; fluid flow; direct compression molding; tensile strength; cryoprotectants; carriers; tablets; food; drugs |
| 01/03/2012 | US8088410 25-hydroxy Vitamin D3 compositions |
| 01/03/2012 | US8088407 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 01/03/2012 | US8088405 Therapeutic compositions and methods |
| 01/03/2012 | US8088401 Composite material comprising a porous semiconductor impregnated with an organic substance |
| 01/03/2012 | US8088388 Complexing; water in oil emulsion; immunostimulant |
| 01/03/2012 | US8088365 Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| 01/03/2012 | US8088357 Tumor-specific recognition molecules |
| 01/03/2012 | US8088095 Polymeric sealant for medical use |
| 01/03/2012 | CA2666341C Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| 01/03/2012 | CA2579619C Radio-opaque polymeric biomaterials |
| 01/03/2012 | CA2529489C Transnasal microemulsions containing diazepam |
| 01/03/2012 | CA2516314C Liquid growth hormone formulation and process of preparation thereof |
| 01/03/2012 | CA2514558C Invert emulsion type composition containing at least one active agent sensitive to the presence of water, and its uses in cosmetics and in dermatology |
| 01/03/2012 | CA2512434C Sustained-release pharmaceutical composition comprising carrageenan for lung administration |
| 01/03/2012 | CA2510040C Polymeric reagents and polymer-biomolecule conjugates comprising carbamate linkages |
| 01/03/2012 | CA2508932C Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 01/03/2012 | CA2496902C Medicament for activating the phagocytic capacity of macrophages |
| 01/03/2012 | CA2493375C Biodegradable phase separated segmented multi block co-polymers |
| 01/03/2012 | CA2491216C Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 01/03/2012 | CA2484184C Minoxidil foam formulation |
| 01/03/2012 | CA2484100C Novel biomaterials, their preparation and use |
| 01/03/2012 | CA2475604C An herpes simplex virus complex |
| 01/03/2012 | CA2466054C Apo-2 ligand/trail formulations |
| 01/03/2012 | CA2463974C Dendrimers for use in targeted delivery |
| 01/03/2012 | CA2463134C Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| 01/03/2012 | CA2457719C Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 01/03/2012 | CA2453243C Treatment of nail infections with no |
| 01/03/2012 | CA2446837C Stable high-concentration injection containing pyrazolone derivative |
| 01/03/2012 | CA2428728C Combination antiperspirant and antimicrobial compositions |
| 01/03/2012 | CA2423220C Modified prodrug forms of ap/amp |
| 01/03/2012 | CA2420618C Percarboxylated polysaccharides, and a process for their preparation |
| 01/03/2012 | CA2419954C Use of il-6r/il-6 chimera in huntington's disease |
| 01/03/2012 | CA2395684C Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 01/03/2012 | CA2374356C Granules containing a plant substance and method for producing the same |
| 01/03/2012 | CA2366433C Staphylococcus antigen and vaccine |
| 01/03/2012 | CA2284000C Hydrophilic binary systems for the administration of cyclosporine |
| 01/03/2012 | CA2264562C Sustained peptide-release formulation |
| 01/03/2012 | CA2248893C Graphitic nanotubes in luminescence assays |
| 01/03/2012 | CA2236591C Continuous low-dose cytokine infusion therapy |
| 01/03/2012 | CA2222889C Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 12/29/2011 | WO2011163483A2 Polymers for biomaterials and therapeutics |
| 12/29/2011 | WO2011163136A2 Tuned multifunctional magnetic nanoparticles for biomedicine |
| 12/29/2011 | WO2011163123A2 Remover in a container |
| 12/29/2011 | WO2011163121A1 Multifunctional copolymers for nucleic acid delivery |
| 12/29/2011 | WO2011162951A1 Compositions and methods for enhancing reduction of spore-forming microorganism |
| 12/29/2011 | WO2011162818A2 Lecithin carrier vesicles and methods of making the same |
| 12/29/2011 | WO2011162752A1 Topical ophthalmic suspensions containing tobramycin and dexamethasone |
| 12/29/2011 | WO2011162639A1 Heterochain aliphatic poly-n-oxide copolymers and vaccinating agents and drugs based thereon |
| 12/29/2011 | WO2011162421A2 Foam-type external skin preparation |
| 12/29/2011 | WO2011162413A1 Sustained-release formulation |
| 12/29/2011 | WO2011162252A1 Branched hetero-polyethylene glycol and intermediate |
| 12/29/2011 | WO2011162094A1 Process for producing emulsifier-producing material, process for producing emulsifier, emulsifier for orally administered composition, and orally administered composition |
| 12/29/2011 | WO2011161531A1 Pharmaceutical composition containing goserelin for in-situ implant |
| 12/29/2011 | WO2011161439A1 Pharmaceutical composition comprising midazolam |
| 12/29/2011 | WO2011161349A1 Novel thickening polymer for ionic oil phases free of monomers |
| 12/29/2011 | WO2011161209A1 Injectable formulation of a macrocyclic lactone and levamisole |
| 12/29/2011 | WO2011161165A1 Long-term storage of non-glycosylated recombinant human g-csf |
| 12/29/2011 | WO2011161075A1 Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| 12/29/2011 | WO2011160849A1 Taste-masked pharmaceutical formulation having accelerated onset of action |
| 12/29/2011 | WO2011160541A1 Tolvaptan solid dispersion and its preparation method |
| 12/29/2011 | WO2011160177A1 Constrained immunogenic compositions and uses therefor |
| 12/29/2011 | WO2011160170A1 Stimulating immune response |
| 12/29/2011 | WO2011160145A1 Use of cellulose in tablets |
| 12/29/2011 | WO2011131510A3 Selective modification of proteins |
| 12/29/2011 | WO2011122934A3 Bioencapsule and method thereof |
| 12/29/2011 | WO2011112840A3 Water-soluble phytosterol derivatives for reducing cholesterol and preparation thereof |
| 12/29/2011 | WO2011109422A3 Compositions and methods for the treatment of cancer |
| 12/29/2011 | WO2011098285A8 Dermatological, pharmaceutical composition suitable for oligonucleotides |
| 12/29/2011 | WO2011097633A3 Egf receptor mimicking peptides |
| 12/29/2011 | WO2011091084A3 Stabilized proteases for use in skin care |
| 12/29/2011 | WO2011090349A3 Nanocarrier having enhanced skin permeability, cellular uptake and tumour delivery properties |
| 12/29/2011 | WO2011089168A3 Special composition for the use thereof as a drug |
| 12/29/2011 | WO2011083112A3 Solid oral dosage form containing olmesartan medoxomil |
| 12/29/2011 | WO2011007327A3 Suspension for therapeutic use and device for delivering said suspension |
| 12/29/2011 | WO2011006596A3 Aqueous solution and gelatinized composition comprising a phosphodiesterase-5 inhibitor and corresponding methods and use |
| 12/29/2011 | WO2010084157A8 Multifunctional stealth nanoparticles for biomedical use |
| 12/29/2011 | US20110319867 Method and device for oral application of a composition |
| 12/29/2011 | US20110319503 Soft capsule based on starch and a method and device for the production thereof |
| 12/29/2011 | US20110319502 Compositions and Methods for Enhancing Reduction of Spore-Forming Microorganisms |
| 12/29/2011 | US20110319500 Alkali swellable acrylic emulsions without surfactants, use thereof in aqueous formulations, and formulations containing them |
| 12/29/2011 | US20110319499 Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease |
| 12/29/2011 | US20110319486 Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same |
| 12/29/2011 | US20110319395 Pharmaceutical Formulation of Olanzapine |
| 12/29/2011 | US20110318406 Lecithin carrier vesicles and methods of making the same |
| 12/29/2011 | US20110318388 S1P Receptors Modulators and Their Use Thereof |
| 12/29/2011 | US20110318369 Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |